Aarti Pharmalabs Limited has informed the Exchange about Investor Presentation
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs submitted its Q4/H2 FY25 investor presentation. FY25 consolidated revenue rose 14.2% YoY to INR 21,151 Mn, with EBITDA up 20.3% at INR 4,644 Mn and EBITDA margin expanding 112 bps to 21.96%. PAT grew 25.6% YoY to INR 2,724 Mn, with diluted EPS at INR 30.04. Q4-FY25 was particularly strong: revenue up 11.5% YoY to INR 5,638 Mn, EBITDA up 23.9% to INR 1,456 Mn (margin of 25.82%, +259 bps), and PAT up 35.2% to INR 883 Mn. The company guided for 12-15% EBITDA growth in FY26, driven by CDMO sales expected to grow 30-40% YoY and Xanthine capacity expansion to 9,000+ MTPA from current 5,000+ MTPA. New Atali greenfield site with 450+ kL reactor capacity expected to commercialise by FY26 end.
Strong FY25 print with margin expansion across both quarterly and annual numbers, plus upbeat FY26 guidance on EBITDA growth and CDMO momentum, should be viewed positively by investors. Capacity expansions in Xanthine and CDMO point to a multi-year growth runway.